Summary of Tactile Medical Conference Call Company Overview - **Company**: Tactile Medical - **Industry**: Medical Technology, specifically focusing on lymphedema and airway clearance products Key Points Financial Performance - Q3 results showed strong performance with beats and raises in both lymphedema and airway clearance businesses [3][4] - The company is in a healthy financial position with cash reserves, retired debt, and stock buybacks [4] Market Opportunity - The lymphedema and bronchiectasis markets are under-penetrated, presenting significant growth opportunities [3][4] - There are approximately 20 million people in the U.S. with lymphedema, but only 2 million are diagnosed, and less than 10% are on medical device therapy [34][35] Strategic Focus - The company is focusing on improving access to care, product innovation, and lifetime value [4] - Investments in CRM and sales force restructuring are aimed at enhancing sales productivity [7][9][10] Product Portfolio - The **Nimble** pump has been successful, leading to market leadership in both basic and advanced pump categories [21][22] - The **FlexiTouch** product is expected to benefit from new reimbursement policies, transitioning from a headwind to a tailwind [14][16][17] Reimbursement Changes - Transition from Local Coverage Determination (LCD) to National Coverage Determination (NCD) is expected to provide a more favorable reimbursement environment [12][14] - The company anticipates seeing positive impacts from these changes in Q4 [16] Innovation and Development - Plans for next-generation products, including enhancements to the AffloVest, are underway, with a focus on portability and connectivity [53] - The company is actively working on expanding its product offerings and improving existing products [22][63] Market Dynamics - The airway clearance market, particularly the AffloVest, is also performing well, with expectations of continued double-digit growth [46][50] - The company is leveraging partnerships with top DMEs to enhance product distribution and awareness [42][44] Future Outlook - The company expects to maintain growth in line with market trends, projecting revenue growth of around 10% for 2026 [54][55] - Continued investments in technology and infrastructure are planned, with a focus on achieving operational leverage [55][57] Capital Allocation - The company has paid down debt and is open to share repurchase programs while maintaining sufficient capital for internal growth and strategic opportunities [57][58] Additional Insights - The company is actively working to raise awareness about lymphedema and improve diagnosis rates, which is crucial for market penetration [36][37] - The competitive landscape for head and neck lymphedema treatment is favorable for Tactile Medical, as it holds unique coverage advantages [33][34] This summary encapsulates the key insights and strategic directions discussed during the Tactile Medical conference call, highlighting the company's strong market position and growth potential in the medical technology sector.

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characte ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Tactile Systems Technology (TCMD) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.Tactile Systems Technology is one of 947 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from ...

Group 1: Stock Highlights - Tactile Systems Technology (TCMD) has seen a 29% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Naspers (NPSNY) has experienced a 20.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - SB Financial Group (SBFG) has recorded a 5.4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3] - OP Bancorp (OPBK) has seen a 4.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [4] - Sony (SONY) has experienced a 4.4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [4]

MINNEAPOLIS, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Piper Sandler 37th Annual Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from December 2nd – 4th. Management will participate in a fireside chat on Tuesday, December 2nd at 8:00 a.m. Central Time. A l ...

Tactile Systems Technology (TCMD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the sy ...

Group 1 - Tactile Systems Technology, Inc. (TCMD) has seen a 29% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Harmony Gold Mining Company Limited (HMY) has experienced a 12.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Robinhood Markets, Inc. (HOOD) has reported a 21.9% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Fabrinet (FN) has seen an 8.6% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - TE Connectivity plc (TEL) has experienced a 7.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Tactile Systems Technology Inc (NASDAQ:TCMD) reported upbeat third-quarter earnings and raised FY2025 sales guidance on Monday.Tactile Systems Tech reported quarterly earnings of 36 cents per share which beat the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $85.755 million which beat the analyst consensus estimate of $79.306 million.Tactile Systems Tech raised its FY2025 sales guidance from $310.000 million-$315.000 million to $317.000 million-$321.000 million.“T ...

Core Insights - Tactile Systems Technology Inc reported strong third-quarter earnings, with earnings per share of 36 cents, surpassing the analyst consensus estimate of 17 cents per share [1] - The company achieved quarterly sales of $85.755 million, exceeding the analyst consensus estimate of $79.306 million [1] - Tactile Systems raised its FY2025 sales guidance from a range of $310 million to $315 million to a new range of $317 million to $321 million [1] Company Performance - CEO Sheri Dodd highlighted the strong third-quarter results as a reflection of ongoing business transformation and product innovation initiatives [2] - The company's go-to-market strategies and differentiated products are contributing to market leadership and revenue growth [2] - Tactile Systems is beginning to see operational leverage and is well-positioned to capitalize on improving market conditions [2] Stock Market Reaction - Following the earnings announcement, Tactile Systems shares surged by 38.1%, reaching a trading price of $21.78 [2] Analyst Ratings - Piper Sandler analyst Adam Maeder maintained a Neutral rating on Tactile Systems and raised the price target from $14 to $20 [5] - Lake Street analyst Ben Haynor kept a Buy rating and increased the price target from $23.5 to $32 [5]

Core Insights - The company reported strong third-quarter financial results, with total revenue of $85.8 million, reflecting a 17% year-over-year growth. Lymphedema revenue increased by 11% to $72.4 million, while airway clearance revenue surged by 71% to $13.4 million [2][31]. - The company raised its full-year 2025 revenue guidance to a range of $317 million to $321 million, indicating an expected growth of approximately 8% to 10% year-over-year [1][35]. Financial Performance - Gross margins improved by 80 basis points year-over-year to 76%, and adjusted EBITDA rose by 34% year-over-year to $14.4 million [1][31]. - Operating expenses increased by 13% to $54 million, driven by strategic investments in sales and marketing [32]. - Net income increased by 59% to $8.2 million, or $0.36 per diluted share, compared to $5.2 million, or $0.21 per diluted share, in the previous year [33]. Business Line Performance - The lymphedema business showed a steady recovery, with a 10% sequential growth and a 130% year-over-year increase in Medicare channel sales [7][10]. - The airway clearance product, AfloVest, experienced a 71% year-over-year growth, attributed to strong partnerships with top respiratory DMEs and increased market awareness of bronchiectasis [12][13]. Strategic Priorities - The company is focused on three strategic priorities: improving access to care, expanding treatment options, and enhancing lifetime patient value [6][20]. - Recent initiatives include integrating AI technology into order operations to improve efficiency and launching a care navigation pilot to enhance patient engagement [18][26]. Market Dynamics - The transition from LCD to NCD in Medicare policies is expected to facilitate greater access to advanced pump therapy, positively impacting revenue growth [36][37]. - The market for lymphedema products is projected to grow at approximately 10%, with the company positioned to capture this growth through enhanced sales strategies and product offerings [60][62]. Capital Allocation - The company is generating free cash flow and has initiated a share repurchase program of up to $25 million, reflecting confidence in its growth trajectory [29][28].